Liver Cancer Diagnostics Market To Reach $17.57 Billion By 2033

August 2025 | Report Format: Electronic (PDF)

Liver Cancer Diagnostics Market Growth & Trends

The global liver cancer diagnostics market size is expected to reach USD 17.57 billion by 2033, registering a CAGR of 6.42% from 2025 to 2033, according to a new report by Grand View Research, Inc. The growing prevalence of liver cancer, the technological advancements for diagnosis, and the awareness of screening importance for treatment & survival rate are driving the market growth for liver cancer diagnostics.

According to the American Society of Cancer statistics in 2022, around 41,260 new cases are expected to be diagnosed with liver cancer. It was also presented by Globocan in 2020, that about 830,180 deaths were accounted by liver cancer worldwide. WHO also estimates that chronic hepatitis viral infections are widespread in the population, with hepatitis C virus (HCV) affecting about 58 million people. HCV and hepatitis B virus (HBV) are the most commonly associated risk factors of liver cancer. In addition, the infection prevalence and exposure to other risk factors such as cirrhosis and smoking will upsurge the demand for screening solutions for early treatment & diagnosis of liver cancer to increase the survival rate. Thus, the demand for diagnostics products will boost during the forecast period, thereby driving market growth.

The COVID-19 pandemic disrupted liver cancer patient care and resulted in higher mortality rates. The delayed or interrupted screening & procedures impacted the patients with the disease. For example, in a June 2021 article, researchers from European countries assessed the pandemic’s impact on routine care of liver cancer patients and concluded that the modifications significantly altered the outcomes. However, with advancements in technology and a better understanding of the immune system during COVID-19, many new healthcare diagnostic products have been launched. Moreover, the pandemic boosted the importance of health and pushed the population toward regular health screening for early diagnosis & treatment.

The technological advancement in diagnosis has resulted from increased awareness and supportive initiatives by many public-private organizations worldwide. This will result in a conducive environment to increase the screening as well as diagnosis of various cancers and is expected to propel the growth of diagnostics solutions. For example, in September 2022, Delfi Diagnostics, Inc., a U.S.-based diagnostics company, announced that it has been selected as the liquid biopsy partner in a large-scale screening trial in Europe.

To cater to the increased demand for innovative solutions for the early detection of liver cancer, multiple companies are launching new products. For instance, in March 2020, F. Hoffmann-La Roche Ltd. Roche received the ‘Breakthrough Device Designation’ from the US FDA for its new Elecsys GALAD score. The score supports clinicians in the diagnosis of hepatocellular carcinoma (HCC) by providing them with timely and accurate information. Key companies are also undergoing collaborations, agreements, and partnerships for new product developments. Such product developments & launches will intensify the market competition and fuel the market growth for liver cancer diagnostics.

key Request a free sample copy or view report summary: Liver Cancer Diagnostics Market Report

Liver Cancer Diagnostics Market Report Highlights

The laboratory tests for liver cancer diagnostics accounted for the largest revenue share of 40.53% and are among the fastest growing, with a CAGR of 7.52% in 2024.
The hospitals & diagnostic laboratories labs segment dominated the End Use segments with the largest market share of 49.26% in 2024.The pharmaceutical and CRO laboratories are expected to grow at the fastest rate with a CAGR of 8.08%.
North America liver cancer diagnostics market dominated the market and accounted for a 40.95% share in 2024.The U.S. liver cancer diagnostics market is expected to expand from 2025 to 2033.
Asia Pacific liver cancer diagnostics market is anticipated to witness the fastest growth of 10.35% CAGR over the forecast period.

Liver Cancer Diagnostics Market Segmentation

Grand View Research has segmented global liver cancer diagnostics market report on the basis of test type, end-use, and region:

Liver Cancer Diagnostics Test type Outlook (Revenue, USD Million, 2021 - 2033)

Laboratory Tests
- Biomarkers
  - Oncofetal and Glycoprotein Antigens
  - Enzymes and Isoenzymes
  - Growth Factors and Receptors
  - Molecular Markers
  - Pathological Biomarkers
- Blood Tests
Imaging
Endoscopy
Biopsy